Geron | GERN - Ebitda

Aktienkurs
1.50
Täglich Wechseln
0 0%
Monatlich
-4.46%
Jährlich
5.63%
Q2 Prognose
1.47




Ebitda Veränderung Datum
Amgen USD 5.14B 775M 2025-12
Bio Techne USD 103.42M 7.47M 2025-12
Cassava Sciences USD -11.73M 33.44M 2025-09
Cytokinetics USD -277.18M 169.36M 2025-09
Esperion Therapeutics USD -9.93M 24.99M 2025-09
Exelixis USD 248.93M 28.02M 2025-09
Genmab DKK 186M 291M 2025-12
Geron USD -9.47M 1.92M 2025-09
Gilead Sciences USD 3.02B 1.01B 2025-12
Incyte USD 414.5M 92.42M 2025-12
MacroGenics USD 21.95M 55.39M 2025-09
Novartis USD 4.77B 1.11B 2025-12
Novavax USD 19.36M 190.79M 2025-12